Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
American Journal of Psychiatry
Fecha de publicación: 14 Jul 2020
DOI: https://doi.org/10.1176/appi.ajp.2020.19080844
Autores: Laura E. Dichtel, M.D., Linda L. Carpenter, M.D., Maren Nyer, Ph.D., David Mischoulon, M.D., Ph.D., Allison Kimball, M.D., Thilo Deckersbach, Ph.D., Darin D. Dougherty, M.D., M.M.Sc., David A. Schoenfeld, Ph.D., Lauren Fisher, Ph.D., Cristina Cusin, M.D., Christina Dording, M.D., et Al
Background: Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation.